Determination of global DNA methylation level by methylation-sensitive comet assay in patients with urinary bladder cancer

• Published in: Mutagenesis 2024-11, Vol.39 (6), p.280-286
• Main Authors: Kocak, Ozer, Kankaya, Selin, Kalender, Goktug, Citgez, Sinharib, Onal, Bulent, Dincer, Yildiz
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - genetics; Comet Assay - methods; DNA Methylation; Female; Humans; Male; Middle Aged; ROC Curve; Urinary Bladder Neoplasms - genetics
• ISSN: 0267-8357; 1464-3804; 1464-3804
• DOI: 10.1093/mutage/geae018

DNA methylation is an important mechanism in the regulation of gene expression and maintenance of genomic integrity. Aberrant DNA methylation is an early event in carcinogenesis. DNA methyltransferase inhibitors are used to restore aberrant DNA methylation and inhibit tumor growth. Evaluation of DNA methylation level is important for an effective anti-cancer therapy. In the present study, the determination of global DNA methylation levels in patients with urinary bladder cancer was proposed. The methylation-sensitive comet assay determined the global DNA methylation level at the level of single cells. McrBC enzyme, a methylation-sensitive restriction endonuclease, was used for enzymatic digestion to generate additional breaks at methylated sites. % DNA methylation level was significantly higher in patients with bladder cancer compared to the control group. The clinical performance of % DNA methylation analysis by methylation-sensitive comet assay was evaluated by ROC curve. Using the cutoff value of 6.5% DNA methylation, 92% sensitivity, and 42% specificity were obtained. In conclusion, global DNA methylation measured by methylation-sensitive comet assay may be a promising noninvasive biomarker that reduces interventional tests required in the diagnosis and follow-up of urinary bladder cancer.